# AZD6738 First Time in Patient Multiple Ascending Dose Study

> **NCT01955668** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2 (actual)

## Conditions studied

- 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),
- Prolymphocytic Leukaemia (PLL)
- B Cell Lymphomas

## Interventions

- **DRUG:** Administration of AZD6738

## Key facts

- **NCT ID:** NCT01955668
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01955668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01955668, "AZD6738 First Time in Patient Multiple Ascending Dose Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01955668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*